Intravenous immunoglobulin for chronic active antibody-mediated rejection: a signal of hope in an evolving field.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 40846400.
- Also identified by DOI 10.1016/j.kint.2025.05.034.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chronic active antibody-mediated rejection remains a leading cause of transplant failure, with no approved therapies and limited clinical guidance. The randomized, open-label VIPAR trial evaluated prolonged high-dose IVIG treatment, providing preliminary evidence of histologic and functional benefits. Despite a small sample size and inherent methodological limitations, the study offers meaningful insights to the limited evidence base and supports further systematic investigation of IVIG as a potential therapeutic option for antibody-mediated rejection.
Medical subject headings
- Immunoglobulins, Intravenous
- Graft Rejection
- Kidney Transplantation